Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Xu-Qing Yang
A Double-Blind, Randomized Phase II Study of Dicycloplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel as First-Line Therapy for Patients With Advanced Non-Small-Cell Lung Cancers
Archives of Medical Science
Medicine
Related publications
Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
A Phase I/Ii Study of Weekly Nab-Paclitaxel Plus Cisplatin in Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Phase II Study of Gemcitabine Plus Oxaliplatin as First-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer
British Journal of Cancer
Cancer Research
Oncology
JCSE01.17 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.16-08 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Phase I/Ii Trial of Pemetrexed Plus Nab-Paclitaxel in Advanced Solid Tumor Patients With Emphasis on Non-Small Cell Lung Cancer
Investigational New Drugs
Oncology
Pharmacology
A Phase Ib/Ii Study of HER3-targeting Lumretuzumab in Combination With Carboplatin and Paclitaxel as First-Line Treatment in Patients With Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
ESMO Open
Cancer Research
Oncology
Nivolumab Plus Carboplatin and Paclitaxel as the First-Line Therapy for Advanced Squamous Cell Carcinoma of the Lung With Strong Programmed Death-Ligand 1 Expression: A Case Report
Cureus
